Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1217012.RAo33WnxnUpuMGROrna4IkC93EUblB1ZX7lxnhBZ5wDow130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1217012.RAo33WnxnUpuMGROrna4IkC93EUblB1ZX7lxnhBZ5wDow130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1217012.RAo33WnxnUpuMGROrna4IkC93EUblB1ZX7lxnhBZ5wDow130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1217012.RAo33WnxnUpuMGROrna4IkC93EUblB1ZX7lxnhBZ5wDow130_provenance.
- NP1217012.RAo33WnxnUpuMGROrna4IkC93EUblB1ZX7lxnhBZ5wDow130_assertion description "[Combination trials of ruxolitinib and novel anti-fibrosing agents such as PRM-151 represent an attempt to address therapeutic limitations of JAK2 inhibitors such as reversal of bone marrow fibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1217012.RAo33WnxnUpuMGROrna4IkC93EUblB1ZX7lxnhBZ5wDow130_provenance.
- NP1217012.RAo33WnxnUpuMGROrna4IkC93EUblB1ZX7lxnhBZ5wDow130_assertion evidence source_evidence_literature NP1217012.RAo33WnxnUpuMGROrna4IkC93EUblB1ZX7lxnhBZ5wDow130_provenance.
- NP1217012.RAo33WnxnUpuMGROrna4IkC93EUblB1ZX7lxnhBZ5wDow130_assertion SIO_000772 25189730 NP1217012.RAo33WnxnUpuMGROrna4IkC93EUblB1ZX7lxnhBZ5wDow130_provenance.
- NP1217012.RAo33WnxnUpuMGROrna4IkC93EUblB1ZX7lxnhBZ5wDow130_assertion wasDerivedFrom befree-2016 NP1217012.RAo33WnxnUpuMGROrna4IkC93EUblB1ZX7lxnhBZ5wDow130_provenance.
- NP1217012.RAo33WnxnUpuMGROrna4IkC93EUblB1ZX7lxnhBZ5wDow130_assertion wasGeneratedBy ECO_0000203 NP1217012.RAo33WnxnUpuMGROrna4IkC93EUblB1ZX7lxnhBZ5wDow130_provenance.
- befree-2016 importedOn "2016-02-19" NP1217012.RAo33WnxnUpuMGROrna4IkC93EUblB1ZX7lxnhBZ5wDow130_provenance.